Cargando…
Interpretation of breast cancer screening guideline for Chinese women
Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women....
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936244/ https://www.ncbi.nlm.nih.gov/pubmed/31908899 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322 |
_version_ | 1783483707208761344 |
---|---|
author | Huang, Yubei Tong, Zhongsheng Chen, Kexin Wang, Ying Liu, Peifang Gu, Lin Liu, Juntian Yu, Jinpu Song, Fengju Zhao, Wenhua Shi, Yehui Li, Hui Xiao, Huaiyuan Hao, Xishan |
author_facet | Huang, Yubei Tong, Zhongsheng Chen, Kexin Wang, Ying Liu, Peifang Gu, Lin Liu, Juntian Yu, Jinpu Song, Fengju Zhao, Wenhua Shi, Yehui Li, Hui Xiao, Huaiyuan Hao, Xishan |
author_sort | Huang, Yubei |
collection | PubMed |
description | Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China. |
format | Online Article Text |
id | pubmed-6936244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Chinese Anti-Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-69362442020-01-06 Interpretation of breast cancer screening guideline for Chinese women Huang, Yubei Tong, Zhongsheng Chen, Kexin Wang, Ying Liu, Peifang Gu, Lin Liu, Juntian Yu, Jinpu Song, Fengju Zhao, Wenhua Shi, Yehui Li, Hui Xiao, Huaiyuan Hao, Xishan Cancer Biol Med Guideline Interpretation Breast cancer is the most common malignant tumor in Chinese women. Early screening is the best way to improve the rates of early diagnosis and survival of breast cancer patients. The peak onset age for breast cancer in Chinese women is considerably younger than those in European and American women. It is imperative to develop breast cancer screening guideline that is suitable for Chinese women. By summarizing the current evidence on breast cancer screening in Chinese women, and referring to the latest guidelines and consensus on breast cancer screening in Europe, the United States, and East Asia, the China Anti-Cancer Association and National Clinical Research Center for Cancer (Tianjin Medical University Cancer Institute and Hospital) have formulated population-based guideline for breast cancer screening in Chinese women. The guideline provides recommendations on breast cancer screening for Chinese women at average or high risk of breast cancer according to the following three aspects: age of screening, screening methods, and screening interval. This article provides more detailed information to support the recommendations in this guideline and to provide more direction for current breast cancer screening practices in China. Chinese Anti-Cancer Association 2019-11 /pmc/articles/PMC6936244/ /pubmed/31908899 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322 Text en Copyright 2019 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Guideline Interpretation Huang, Yubei Tong, Zhongsheng Chen, Kexin Wang, Ying Liu, Peifang Gu, Lin Liu, Juntian Yu, Jinpu Song, Fengju Zhao, Wenhua Shi, Yehui Li, Hui Xiao, Huaiyuan Hao, Xishan Interpretation of breast cancer screening guideline for Chinese women |
title | Interpretation of breast cancer screening guideline for Chinese women |
title_full | Interpretation of breast cancer screening guideline for Chinese women |
title_fullStr | Interpretation of breast cancer screening guideline for Chinese women |
title_full_unstemmed | Interpretation of breast cancer screening guideline for Chinese women |
title_short | Interpretation of breast cancer screening guideline for Chinese women |
title_sort | interpretation of breast cancer screening guideline for chinese women |
topic | Guideline Interpretation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936244/ https://www.ncbi.nlm.nih.gov/pubmed/31908899 http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0322 |
work_keys_str_mv | AT huangyubei interpretationofbreastcancerscreeningguidelineforchinesewomen AT tongzhongsheng interpretationofbreastcancerscreeningguidelineforchinesewomen AT chenkexin interpretationofbreastcancerscreeningguidelineforchinesewomen AT wangying interpretationofbreastcancerscreeningguidelineforchinesewomen AT liupeifang interpretationofbreastcancerscreeningguidelineforchinesewomen AT gulin interpretationofbreastcancerscreeningguidelineforchinesewomen AT liujuntian interpretationofbreastcancerscreeningguidelineforchinesewomen AT yujinpu interpretationofbreastcancerscreeningguidelineforchinesewomen AT songfengju interpretationofbreastcancerscreeningguidelineforchinesewomen AT zhaowenhua interpretationofbreastcancerscreeningguidelineforchinesewomen AT shiyehui interpretationofbreastcancerscreeningguidelineforchinesewomen AT lihui interpretationofbreastcancerscreeningguidelineforchinesewomen AT xiaohuaiyuan interpretationofbreastcancerscreeningguidelineforchinesewomen AT haoxishan interpretationofbreastcancerscreeningguidelineforchinesewomen |